Affimed (AFMD) said Monday that AFM28 showed "promising" efficacy and safety results evaluating the drug candidate in patients with relapsed/refractory acute myeloid leukemia in an ongoing phase 1 study.
The drug candidate reached a 40% composite complete remission rate at the highest dose level of 300 milligrams in heavily pretreated patients, the company said.
The company said AFM28 showed a "favorable" safety profile, with no signs of neurotoxicity or immune-related side effects seen.
Affimed said the assessment of higher dose levels is being planned, based on the safety profile and the likely dose-effect relationship.
Price: 2.27, Change: -0.06, Percent Change: -2.58
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。